Two out of three people with metastatic disease survive 5 years or more, the report shows. The authors hope the data can help researchers develop better cancer control programs.
Two out of 3 Americans with invasive cancer—the kind that has spread to nearby healthy tissue—are living 5 years or more after diagnosis, according to a new report from the CDC.
Data have shown that early detection and innovation in cancer treatment have increased the number of cancer survivors over the last several years, and the new report, published in the CDC’s Morbidity and Mortality Weekly Report, shows that even patients with invasive cancer have encouraging survival rates.
To reach these numbers, CDC researchers looked at the number of cancer cases reported to U.S. cancer registries in 2011, the year of the most recently available data. That year saw 1,532,066 invasive cancer cases, or 451 cases per 100,000 people.
The CDC reports that the most common cancer sites were prostate, breast, lung, and colon, and rectum. The 5-year survival rates for those cancers came out to 97% for prostate cancer, 88% for breast cancer, 63% for colorectal cancer and 18% for lung cancer. While the rates were relatively even among men and women, racial disparities existed; 65% of white people had a 5-year relative survival rate, and 60% of black people had the same.
Link to the TIME article:
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More